Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. (2023)
Attributed to:
COVID-19: Data and Connectivity – National Core Study (D&C-NCS)
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2022-327570
PubMed Identifier: 35902214
Publication URI: http://europepmc.org/abstract/MED/35902214
Type: Journal Article/Review
Volume: 72
Parent Publication: Gut
Issue: 2
ISSN: 0017-5749